AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern

NEXT STORY
Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management
PREV STORY
Axiom Medical, an innovator in occupational health services for employers, announced it has exceeded ten million check ins on the leading edge CheckIn2Work mobile app
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Hospital Acquired Disease Testing Market Report 2018: $1.72 Billion Market Trends, Share, Size, Growth, Opportunity and Forecasts 2017-2023

Dublin, Jan. 11, 2019 (GLOBE NEWSWIRE) -- The "Hospital Acquired Disease Testing Market: Global ...

author_avatar
NASDAQ Market News

Helix BioPharma Corp. Initiates Enrollment of the Second Last Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

RICHMOND HILL, Ontario, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: ...

author_avatar
NASDAQ Market News

Calithera Biosciences Announces CB-839 Preclinical Data Selected for Presentation at the 58th American Society of Hematology Annual Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), ...

author_avatar
NASDAQ Market News